(CercleFinance.com) – Eurobio Scientific revealed yesterday evening declining results for the 2023 financial year, but set itself the objective of returning to growth in its turnover and its margins.
Penalized by the end of the effect linked to Covid, the specialist in in vitro medical diagnostics and life sciences saw its operating profit fall by 39% last year to 22.5 million euros.
Its 2023 net profit stands at 4.8 million euros, down 81%.
In its press release, the group explains that it has also suffered from its ongoing strategic transformation, notably with the full-year integration of GenDx.
Eurobio nevertheless underlines the ‘good resistance’ of its results, highlighting the generation of free cash flow of 26.4 million euros over the entire financial year.
At the end of December 2023, the company had cash of 89 million euros, for a financial debt of 94.5 million euros.
Eurobio Scientific now says it wants to continue the deployment of its priority strategic axes, namely the development of its own products and internationalization with the opening of new markets.
The idea being to achieve both growth in turnover and an increase in margins.
Listed on the Paris Stock Exchange, the stock fell 3.5% on Thursday morning following this publication.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
